Dynamic Technology Lab Private Ltd acquired a new stake in shares of NuVasive, Inc. (NASDAQ:NUVA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 24,998 shares of the medical device company’s stock, valued at approximately $1,774,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in NUVA. Anchor Capital Advisors LLC grew its stake in NuVasive by 1,205.1% during the 2nd quarter. Anchor Capital Advisors LLC now owns 983,977 shares of the medical device company’s stock valued at $51,285,000 after acquiring an additional 908,582 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of NuVasive by 100.0% in the 3rd quarter. Victory Capital Management Inc. now owns 1,000,605 shares of the medical device company’s stock valued at $71,023,000 after buying an additional 500,395 shares during the period. Investment Counselors of Maryland LLC purchased a new stake in shares of NuVasive in the 3rd quarter valued at approximately $21,782,000. Glenmede Trust Co. NA purchased a new stake in shares of NuVasive in the 2nd quarter valued at approximately $12,955,000. Finally, Eagle Asset Management Inc. grew its stake in shares of NuVasive by 12.8% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,267,961 shares of the medical device company’s stock valued at $66,086,000 after buying an additional 143,926 shares during the period.

Shares of NUVA stock opened at $57.86 on Friday. The company has a current ratio of 3.45, a quick ratio of 1.83 and a debt-to-equity ratio of 0.74. NuVasive, Inc. has a one year low of $44.62 and a one year high of $72.41. The company has a market capitalization of $3.05 billion, a PE ratio of 28.38, a P/E/G ratio of 1.78 and a beta of 0.80.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, October 30th. The medical device company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.06). NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The company had revenue of $271.30 million during the quarter, compared to analyst estimates of $265.70 million. During the same quarter in the prior year, the company posted $0.52 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. Equities analysts expect that NuVasive, Inc. will post 2.18 earnings per share for the current year.

In other news, insider Matthew Link sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $62.01, for a total value of $74,412.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 8,671 shares of company stock worth $538,741. Company insiders own 1.20% of the company’s stock.

Several analysts have recently weighed in on NUVA shares. BidaskClub cut shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Piper Jaffray Companies increased their price target on shares of NuVasive to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, August 14th. BTIG Research increased their price target on shares of NuVasive to $72.00 and gave the company a “buy” rating in a research note on Thursday, August 16th. Zacks Investment Research raised shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, August 21st. Finally, Cowen increased their price target on shares of NuVasive from $62.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $66.82.

WARNING: “Dynamic Technology Lab Private Ltd Acquires New Position in NuVasive, Inc. (NUVA)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2018/12/07/dynamic-technology-lab-private-ltd-acquires-new-position-in-nuvasive-inc-nuva.html.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Article: How dollar cost averaging works

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.